Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 61-70

  Ramani, Gautam V ^a   Park, Myung H ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Phosphodiesterase type 5 inhibitor; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

ANOREXIGENIC AGENT; BOSENTAN; ILOPROST; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VASODILATOR AGENT;

6 MINUTE WALK DISTANCE; ABNORMAL LABORATORY RESULT; BLURRED VISION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; COMBINATION CHEMOTHERAPY; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EPISTAXIS; EXERCISE; FLUSHING; FUNCTIONAL ASSESSMENT; HEADACHE; HEART FAILURE; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; PORTOPULMONARY HYPERTENSION; PULMONARY HYPERTENSION; QUALITY OF LIFE; RETINA HEMORRHAGE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VASODILATATION; CLINICAL TRIAL; ECONOMICS;

CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION, PULMONARY; PIPERAZINES; PURINES; SULFONES; VASODILATOR AGENTS;

EID: 77957100641     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/dddt.s6208     Document Type: Review

References (70)

1. Humbert M, Sibton O, Chaout A, et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med.2006;173: 1023-1026.
2. Butrous G, Ghofrani HA, Grimminger F. Pulmonary vascular diseases in the developing world. Circulation. 2008;118: 1758-1766.
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115: 343-349.
4. McLaughlin VV, Sibton O, Badesch DB, et al. Survival with first-linebosentan in patients with primary pulmonary hypertension. Eur Respir J.2005;25: 244-249. Erratum in Eur Respir J. 2005;25:942.
5. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts andtranslational priorities in pulmonary arterial hypertension. Circulation.2008;118: 1486-1495.
6. Archer SL, Michelakis ED. Phospho diesterase type 5 Inhibitors for pulmonaryarterial hypertension. N Engl J Med. 2009;361: 1864-1861.
7. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338: 1397-1404.
8. Galie N, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353: 2148-2157.
9. Lucas KA, Pitari GM, Kazerounian S, et al. Guanyl cyclases andsignalingby cyclic GMP. Pharmacol Rev. 2000;52: 375-413.
10. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiologyand pharmacology. Pharmacol Rev. 1991;43: 109-142.
11. Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect ofsildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005;100: 131-138.
12. Girgis RE, Champion HC, Diette GB, et al. Decreased exhaled nitricoxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med. 2005;172: 352-357.
13. Beall CM, Laskowski D, Strohl KP, et al. Pulmonary nitric oxide inmountain dwellers. Nature. 2001;414: 411-412.
14. Wang C, Wang J, Zhao L, et al. Sildenafil inhibits human pulmonaryartery smooth muscle cell proliferation by decreasing capacitative Ca2+entry. J Pharmacol Sci. 2008;108: 71-78.
15. Francis SH, Corbin JD. Sildenafil: efficacy, safety, tolerability andmechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol. 2005;1: 283-293.
16. Wharton J, et al. Antiproliferative effects of phosphodiesterase type 5inhibition in human pulmonary artery cells. Am J Respir Crit Care Med.2005;172: 105-113.
17. Corbin JD, Beasley A, Blount MA, et al. High lung PDE5: a strong basisfor treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334: 930-938.
18. Haynes J, Kithas PA, Taylor AE, et al. Selective inhibition of cGMPinhibitablecAMP phosphodiesterase decreases pulmonary vasoreactivity. Am J Physiol. 1991;261:H487-H492.
19. Zhao L, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104: 424-429.
20. Kosmicki MA. Long-term use of short and long-acting nitrates in stableangina pectoris. Curr Clin Pharmacol. 2009;4: 132-141.
21. Abdollahi M, Fooladian F, Emani B, et al. Protection by sildenafil andtheophylline of lead acetate-induced oxidative stress in rat submandibulargland and saliva. Hum Exp Toxicol. 2003;22: 587-592.
22. Perk H, Armagan A, Naziroglu M, et al. Sildenafil citrate as a phosphodiesteraseinhibitor has an antioxidant effect in the blood of men. J Clin Pharm Ther. 2008;33: 635-640.
23. Nagendran J, Archer SL, Soliman D, et al. Phospho diesterase type 5is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphor diesterase type 5 improves contractility. Circulation. 2007;116: 238-248.
24. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation.2002;105: 2398-2403.
25. Lepore JJ, Maroo A, Bigatello LM, et al. Hemo dynamic effects ofsildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest.2005;127: 1647-1653.
26. Diller GP, van Eijl S, Okonko Do, et al. Circulation endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathicpulmonary arterial hypertension. Circulation. 2008;117: 3020-3030.
27. Schermuly RT, Pullamsetti SS, Kwapiszewska G, et al. Phosphodiesterase1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation. 2007;115: 2331-2339.
28. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1:5S-12S.
29. Muirhead GJ, Wilner K, Colburn W, et al. The effects of age and renaland hepatic impairment on the pharmacokinetics of sildenafil. Br J ClinPharmacol. 2002;53 Suppl 1:21S-30S.
30. Revatio.com [Home page on the internet] Updated 11/2009. http://www.revatio.com/intermediateLaunch.aspx Accessed 12/27/2009. AccessedDec 2009.
31. Huang S, Hermes DeSantis, Evelyn R. Treatment of pulmonary arterial hypertension in pregnancy. Am J Health Syst Pharm. 2007;64: 1922-1926.
32. Webb DJ, Freestone S, Allen MJ. Sildenafil citrate and blood-pressureloweringdrugs: results of drug interaction studies with an organic nitrateand a calcium antagonist. Am J Cardiol. 1999; 83:21C-28C.
33. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36: 25-31.
34. Jackson G, Benjamin N, Jackson N, et al. Effects of sildenafil citrateon human hemodynamics. Am J Cardiol. 1999;83:13C-20C.
35. Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf. 2009;32: 1-18.
36. Philip A, Ramachandani S, Dorrance K, et al. Sildenafil-induced thrombocytopenia. Ann Intern Med. 2008;149: 437-439.
37. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonaryhypertension. N Engl J Med. 2000;343:1342.
38. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide with drawal. Anesthesiology. 1999;91: 307-310.
39. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol.2004;43: 1149-1153.
40. Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterialhypertension associated with connective tissue disease. J Rheumatol.2007;34: 2417-2422.
41. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment withoral sildenafil is safe and improves functional capacity and hemodynamicsin patients with pulmonary arterial hypertension. Circulation.2003;108: 2066-2069.
42. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009expert consensus document on pulmonary hypertension: a report ofthe American College of Cardiology Foundation Task Force on ExpertConsensus Documents and the American Heart Association developedin collaboration with the American College of Chest Physicians;American Thoracic Society, Inc.; and the Pulmonary HypertensionAssociation. J Am Coll Cardiol. 2009;53: 1573-1619.
43. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus EndothelinReceptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am J Respir Crit Care Med. 2005;171: 1292-1297.
44. Hemmes AR, Robbins IM. Sildenafil monotherapy in portopulmonaryhypertension can facilitate liver transplantation. Liver Transpl.2009;15: 15-19.
45. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to longtermintravenous Epoprostenol therapy in patients with pulmonaryarterial hypertension. Ann Intern Med. 2008;149: 521-530.
46. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as longtermadjunct therapy to inhaled iloprost in severe pulmonary arterialhypertension. J Am Coll Cardiol. 2003;42: 158-164.
47. Burgess G, Hoogkamer H, Collings L, et al. Mutual pharmacokineticinteractions between steady-state bosentan and sildenafil. Eur J ClinPharmacol. 2008;64: 43-50.
48. Gruenig E, Michelakis E, Vachiery JL, et al. Acute hemodynamiceffects of single-dose sildenafil when added to established bosentantherapy in patients with pulmonary arterial hypertension: results of theCOMPASS-1 study. J Clin Pharmacol. 2009;49: 1343-1352.
49. Spence R, Mandagere A, Dufton C, et al. Pharmacokinetics and safetyof ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol. 2008;48: 1451-1459.
50. Gann MC, Clark L, Chumney EC, et al. Cost-utility of treatment for pulmonary arterial hypertension: a Markov state-transition decisionanalysis model. Clin Drug Investig. 2009;29: 635-646.
51. Galie N, Bundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonaryarterial hypertension. Circulation. 2009;119: 2894-2903.
52. Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic interaction between tadalafil and bosent an in healthy male subjects. J Clin Pharmacol.2008;48: 610-618.
53. Reichenberger F, et al. Long-term treatment with sildenaf il inchronic thromboembolic pulmonary hypertension. Eur Respir J.2007;30: 922-927.
54. DeSanto LS, Mastroianni C, Romano G, et al. Role of sildenafil in acuteposttransplant right ventricular dysfunction: successful experience in13 consecutive patients. Transplant Proc. 2008;40: 2015-2018.
55. Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in endstage pulmonary sarcoidosis: therapeutic effect of sildenafil? J HeartLung Transplant. 2008;27: 329-334.
56. Holverda S, Rietema H, Bogaard HJ, et al. Acute effects of sildenafilon exercise pulmonary hemodynamics and capacity in patients withCOPD. Pulm Pharmacol Ther. 2008;21: 558-564.
57. Richalet JP, Gratadour P, Robach P, et al. Sildenafil inhibits altitudeinducedhypoxemia and pulmonary hypertension. Am J Respir CritCare Med. 2005;171: 275-281.
58. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment oflung fibrosis and pulmonary hypertension: a randomized controlledtrial. Lancet. 2002;360: 895-900.
59. Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment ofRaynaud's phenomenon resistant to vasodilatory therapy. Circulation.2005;112: 2980-2985.
60. Hoeper MM, Barbera JA, Channick RN, et al. Diagnosis, assessment,and treatment of non-pulmonary arterial hypertension pulmonaryhypertension. J Am Coll Cardiol. 2009;54:S85-S96.
61. Katz SD, Parker JD, Glasser DB, et al. Efficacy and safety of sildenafilcitrate in men with erectile dysfunction and chronic heart failure. Am JCardiol. 2005;95: 36-42.
62. Packer M, Carver JR, Rodeheffer RJ, et al; for the PROMISE study research group. Effect of oral milrinone on mortality in severe chronicheart failure. N Engl J Med. 1991;325: 1468-1475.
63. Melenovsky V, Al-Hiti H, Kazdova L, et al. Transpulmonary B-typenatriuretic peptide uptake and cyclic guanosine monophosphate releasein heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol. 2009;54: 595-600.
64. Lewis GD, Shah RV, Pappagianopolas PP, et al. Determinants of ventilatorefficiency in heart failure: the role of right ventricular performanceand pulmonary vascular tone. Circ Heart Fail. 2008;1: 227-233.
65. Behling A, Rohde LE, Colombo FC, et al. Effect of 5'-phosphodiesterasefour-week long inhibition with sildenafil in patients with chronic heartfailure: a double-blind placebo-controlled clinical trial. J Card Fail.2008;14: 189-197.
66. Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafilin the therapeutic management of heart failure. J Am Coll Cardiol.2007;50: 2136-2144.
67. Stehlik J, Movsesian MA. Combined use of PDE5 inhibitors and nitratesin the treatment of pulmonary arterial hypertension patients with heartfailure. J Card Fail. 2009;15: 31-34.
68. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterialhypertension. N Engl J Med. 2004;351: 1425-1436.
69. Barst RJ, editor. Pulmonary Arterial Hypertension: Diagnosis and Evidence-Based Treatment. West Sussex, England. John Wiley &Sons; 2008.
70. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation.2006;114: 1417-1431.